Neuromodulation (GPi-DBS or pallidotomy) has been successful in controlling paroxysmal exacerbations and evolution into status dystonicus in GNAO1, GNB1, and PDE2A-related MDs. The gene discussed is PDE2A; the disease is myelodysplastic syndrome.